Dry Skin Coping Strategies
Dry skin is a common problem among GIST patients. There are many things that you can do to alleviate dry skin caused by GIST treatment. Keep reading for more info. Dry Skin Coping Strategies: Using [...]
Necrosis of the Jaw Coping Strategies
Necrosis of the jaw has been reported to occur in some patients receiving bisphophonate therapy. There have been several reports of possible drug interaction between sunitinib (Sutent) and bisphophonates that significantly increases the risk of necrosis [...]
Edema Coping Strategies
Between fifty to seventy percent of GIST patients participating in Gleevec clinical trials are reported to have edema according to the Life Raft Group survey (October, 2001) and www.gleevec.com. Edema can develop in different [...]
Mouth Sores – Coping Strategies
Mouth sores, or stomatitis as it is referred to in medical textbooks, can develop as a result of cancer treatment. There are many ways to help prevent and reduce the occurrence of mouth sores. How [...]
Increased Tearing – Epiphoria Coping Strategies
Increased tearing, or epiphoria, can be a side effect of your GIST treatment. There are a number of strategies to cope with increased tearing. Keep reading for more information. Here are a few strategies [...]
Hand and Foot Syndrome Coping Strategies
Hand and Foot Syndrome coping strategies. Although targeted cancer therapies are generally considered to have less side effects than traditional chemotherapy, the need to take these drugs for extended time periods (in many cases [...]
Muscle Cramps – Coping Strategies
Updated 2/9/2022 Muscle cramps can occur during cancer treatment, and it is a common side effect patients in our Patient Registry experience. GIST Treatments including Gleevec, Sutent, Stivarga, Qinlock and Ayvakit can cause a [...]
Michigan Local Group Meeting a Success
We had a good turnout at the Michigan LRG meeting on Saturday. Keep reading to learn more about the importance of local group meetings.
Life Raft Group Canada Issues Latest Newsletter
Life Raft Group, Canada has just issued Vol. 3, Issue 2, of its Newsletter. This issue is 8 pages in length, and features several interesting articles.
ARIAD Launches Phase 2 trial of Iclusig to treat GIST
ARIAD Pharmaceuticals has launched a Phase 2 trial of Iclusig to treat GIST. Keep reading for all the details in the official press release.